201 related articles for article (PubMed ID: 33565048)
41. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration.
Finch AP; Meregaglia M; Ciani O; Roudijk B; Jommi C
Soc Sci Med; 2022 Jan; 292():114519. PubMed ID: 34736804
[TBL] [Abstract][Full Text] [Related]
42. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
[TBL] [Abstract][Full Text] [Related]
43. In search of a 'pan-European value set'; application for EQ-5D-3L.
Sajjad A; Versteegh MM; Santi I; Busschbach J; Simon J; Roijen LH
BMC Med Res Methodol; 2023 Jan; 23(1):13. PubMed ID: 36635625
[TBL] [Abstract][Full Text] [Related]
44. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran.
Goudarzi R; Sari AA; Zeraati H; Rashidian A; Mohammad K; Amini S
Value Health Reg Issues; 2019 May; 18():170-175. PubMed ID: 31096140
[TBL] [Abstract][Full Text] [Related]
45. A national survey of Iranian general population to estimate a value set for the EQ-5D-5L.
Afshari S; Daroudi R; Goudarzi R; Mahboub-Ahari A; Yaseri M; Sari AA; Ameri H; Bahariniya S; Oliaei-Manesh A; Kalavani K; Zare Z; Hasannezhad E; Mirzaei M; Amiri Z
Qual Life Res; 2023 Jul; 32(7):2079-2087. PubMed ID: 36897530
[TBL] [Abstract][Full Text] [Related]
46. Why Do Adults Value EQ-5D-Y-3L Health States Differently for Themselves Than for Children and Adolescents: A Think-Aloud Study.
Reckers-Droog V; Karimi M; Lipman S; Verstraete J
Value Health; 2022 Jul; 25(7):1174-1184. PubMed ID: 35168891
[TBL] [Abstract][Full Text] [Related]
47. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
48. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
[TBL] [Abstract][Full Text] [Related]
49. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
50. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
[TBL] [Abstract][Full Text] [Related]
51. Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L.
Chemli J; Drira C; Felfel H; Roudijk B; Al Sayah F; Kouki M; Kooli A; Razgallah Khrouf M
Qual Life Res; 2021 May; 30(5):1445-1455. PubMed ID: 33447958
[TBL] [Abstract][Full Text] [Related]
52. Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology.
Lipman SA; Zhang L; Shah KK; Attema AE
Eur J Health Econ; 2023 Mar; 24(2):293-305. PubMed ID: 35596831
[TBL] [Abstract][Full Text] [Related]
53. Population health status based on the EQ-5D-Y-3L among adolescents in Sweden: Results by sociodemographic factors and self-reported comorbidity.
Åström M; Persson C; Lindén-Boström M; Rolfson O; Burström K
Qual Life Res; 2018 Nov; 27(11):2859-2871. PubMed ID: 30196340
[TBL] [Abstract][Full Text] [Related]
54. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
55. The EQ-5D-5L Valuation study in Thailand.
Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
[TBL] [Abstract][Full Text] [Related]
56. Comparing Quality of Life of General Population and Orthopedic Patients in Slovenia.
Prevolnik Rupel V; Slabe-Erker R; Divjak M
Value Health Reg Issues; 2020 Sep; 22():93-98. PubMed ID: 32823061
[TBL] [Abstract][Full Text] [Related]
57. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
Ludwig K; von der Schulenburg JG; Greiner W
Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
[TBL] [Abstract][Full Text] [Related]
58. Feasibility of Proxy-Reported EQ-5D-3L-Y and Its Agreement in Self-reported EQ-5D-3L-Y for Patients With Adolescent Idiopathic Scoliosis.
Lin J; Wong CKH; Cheung PWH; Luo N; Cheung JPY
Spine (Phila Pa 1976); 2020 Jul; 45(13):E799-E807. PubMed ID: 32539293
[TBL] [Abstract][Full Text] [Related]
59. The Indonesian EQ-5D-5L Value Set.
Purba FD; Hunfeld JAM; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Ramos-Goñi JM; Passchier J; Busschbach JJV
Pharmacoeconomics; 2017 Nov; 35(11):1153-1165. PubMed ID: 28695543
[TBL] [Abstract][Full Text] [Related]
60. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
